Benzinga | Oct 20, 2021 05:49AM EDT

Needham Maintains Buy on Sage Therapeutics, Lowers Price Target to $79

Needham analyst Ami Fadia maintains Sage Therapeutics (NASDAQ:SAGE) with a Buy and lowers the price target from $84 to $79.